Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Correspondent
ACR 2017
ASCO 2017 - Acute Myeloid Leukemia
ASCO 2017 - Chronic Lymphocytic Leukemia
ASCO 2019 - Chronic Lymphocytic Leukemia
ASCO 2020 - Lung Cancer
ASCO 2021 - GU Highlights
ASH 2016 - Chronic Lymphocytic Leukemia
ASH 2016 - Multiple Myeloma
ASH 2017 - Chronic Lymphocytic Leukemia
ASH 2018 - Chronic Lymphocytic Leukemia
ASH 2019 - Chronic Lymphocytic Leukemia
Conference Highlights ADA
Conference Highlights AHA
Conference Highlights AMCP
Conference Highlights ASCO
Conference Highlights ASH
Conference Highlights Digestive Disease Week
Conference Highlights ISPOR
Conference Highlights NCCN
Conference Highlights SABCS
IDWeek 2018
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Pomalidomide and Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Salvage Use of Ibrutinib After allo-HSCT for B-Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Society for Blood and Marrow Transplantation (SFGM-TC), and the EBMT Chronic Malignancy and Lymphoma Working Parties
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed by GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Trial
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multicenter Study of 683 US Patients
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft-versus-Host Disease (cGVHD) After Failure of Corticosteroids
Read More
2
3
4
5
6
7
8
Page 5 of 8
Results 41 - 50 of 80